Preventive Medicine Doctors in Jacksonville, FL Accepting Medicare

26 Preventive Medicine doctors found. Showing 21 - 26

Monees Hussain Syed, M.D, MPH. Preventive Medicine - Public Health & General Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: Concentra Urgent Care, 5995-1 University Blvd, West, Jacksonville, FL 32216 Phone: 701-293-4113

Dr. Robert Gerald Harmon, MD Preventive Medicine - Public Health & General Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 515 W 6th St, Mc #33, Jacksonville, FL 32206 Phone: 904-630-3220    Fax: 904-359-2666

Liberto Colombo Jr., DO Preventive Medicine - Aerospace Medicine Medicare: Medicare Enrolled Practice Location: 9063 Starpass Dr, Jacksonville, FL 32256 Phone: 850-529-0040

Dr. Marion Anderson Gregg Ii, M.D., M.P.H, M.B.A Preventive Medicine - Public Health & General Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2080 Child St Dept 5000, Jacksonville, FL 32214 Phone: 904-524-9109

Lenka Zachar, MD Preventive Medicine - Undersea and Hyperbaric Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Shircliff Way Ste 520, Jacksonville, FL 32204 Phone: 904-308-5266    Fax: 904-308-5267

Dr. Chris John Kane, D.O. Preventive Medicine - Aerospace Medicine Medicare: Accepting Medicare Assignments Practice Location: 2165 Herschel St, Jacksonville, FL 32204 Phone: 904-387-4030

News Archive

New test predicts breast cancer relapse months in advance

UK-based researchers have developed a blood test that can predict whether patients with breast cancer will experience a relapse after receiving treatment, months before tumors are visible using hospital scans.

Better management of asthma possible

Better management of asthma in the community is not only possible, but has the potential to reduce the impact of the disease on people's lives, according to a report by the Australian Centre for Asthma Monitoring (ACAM) , a collaborating unit of the Australian Institute of Health and Welfare.

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

New grant to enable University of Rochester to increase HIV research by 25 percent

The University of Rochester today announced that the National Institutes of Health (NIH) has awarded a team of more than 50 researchers a five-year, $3.2 million grant.

Read more Medical News

› Verified 1 days ago

• 1
• 2(current)